Effect of recombinant human erythropoietin combined with sucrose iron on anemia status and CysC,CRP levels in hemodialysis patients with diabetes nephropathy
Objective:To analyze the therapeutic effect of recombinant human erythropoietin combined with sucrose iron on hemodialysis patients with diabetes nephropathy(DN).Methods:98 cases of DN hemodialysis patients treated in our hospital from March 2020 to March 2022 were randomly divided into control group and observation group with 49 cases in each group.The control group was given recombinant human erythropoietin,and the observation group was given recombinant human erythropoietin and sucrose iron.The clinical efficacy,anemia status,inflammatory status,renal function and adverse reactions were compared between the two groups.Results:The total effective rate in the observation group was higher than that in the control group(P<0.05);After treatment,the levels of anemia status indexes in the observation group were higher than those in the control group,the levels of inflammatory status and renal function were lower than those in the control group(P<0.05);There was no significant difference in the incidence of adverse reactions between the two groups.Conclusion:Recombinant human erythropoietin combined with sucrose iron can improve anemia status and renal function,and alleviate inflammation in DN hemodialysis patients.
Recombinant human erythropoietinSucrose ironDiabetes nephropathyHemodialysisAnemia
万方数据
维普
